Tuesday, May 21, 2013 Last update: 6:04 AM
Company Tech News as it Breaks
Trade Events
Advanced Cell Technology, Inc.
News articles for Advanced Cell Technology, Inc.:
Thursday, May 16, 2013
- ACT Confirms Clinical Trial Participant Showed Improvement in Vision from 20/400 to 20/40 Following TreatmentAdvanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today confirmed that the vision of a patient enrolled in a clinical ... read more
Thursday, May 9, 2013
- Advanced Cell Technology Announces 2013 First Quarter ResultsAdvanced Cell Technology, Inc. (“ACT” or the ”Company”; OTCBB: ACTC) a leader in the field of regenerative medicine, announced today its first quarter financial results for the period ... read more
Monday, May 6, 2013
- Advanced Cell Technology to Host Conference Call to Discuss 2013 First Quarter Results and Provide a Corporate Update on Thursday, May 9thAdvanced Cell Technology, Inc. (“ACT”, OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will release its first quarter financial results for the ... read more
Tuesday, April 23, 2013
- ACT Initiates Higher-Dosage Patient Treatment in European Clinical Trial for Macular DegenerationAdvanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the first patient in the third dosage cohort, and ... read more
Tuesday, April 16, 2013
- Advanced Cell Technology to Present at Regen Med Investor Day 2013Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced that Chairman and CEO Gary Rabin will present at the Alliance ... read more
Monday, April 15, 2013
- ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt’s Macular DystrophyAdvanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the first patient in patient cohort 2a, consisting of ... read more
Tuesday, March 12, 2013
- ACT’s Dr. Robert Lanza Voted Top 4 “Most Influential People on Stem Cells”Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that chief scientific officer Robert Lanza, M.D., is featured on ... read more
Friday, March 8, 2013
- Advanced Cell Technology to Present at BIO-Europe Spring 2013Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that chairman and CEO Gary Rabin will present and participate on ... read more
Thursday, March 7, 2013
- Advanced Cell Technology Announces Fourth-Quarter and Year-end ResultsAdvanced Cell Technology, Inc. (“ACT”, OTCBB: ACTC or the “Company”), a leader in the field of regenerative medicine, today announced fourth quarter and year-end financial results for the ... read more
Monday, March 4, 2013
- Advanced Cell Technology to Announce Fourth Quarter and Year-end Results on Thursday March 7thAdvanced Cell Technology, Inc. (“ACT”;OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will report fourth quarter and year-end results for the ... read more
Monday, February 11, 2013
- ACT’s Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief of BioResearch Open Access JournalAdvanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the regenerative medicine space, announced today that the Company’s chief scientific officer, Robert Lanza, MD, ... read moreACT’s Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using the Company’s hESC-derived Cells to Treat Severe MyopiaAdvanced Cell Technology, Inc.’s (“ACT”; OTCBB: ACTC or the “Company”), clinical partner, the University of California, Los Angeles (UCLA), has received approval of its Investigator Investigational New Drug ... read more
Friday, February 8, 2013
- Advanced Cell Technology to Present at 15th Annual BIO CEO & Investor ConferenceAdvanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that chairman and CEO Gary Rabin will present ... read more
Tuesday, January 22, 2013
- Patients with Better Vision to be Enrolled in ACT’s Clinical Trials for Macular DegenerationAdvanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the field of regenerative medicine, announced today that it is amending the patient treatment ... read more
Thursday, January 17, 2013
- Advanced Cell Technology Announces Settlement of LitigationAdvanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the field of regenerative medicine, today announced that it has reached a settlement agreement with ... read more
Tuesday, January 8, 2013
- Advanced Cell Technology Achieves Clinical MilestoneAdvanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the field of regenerative medicine, announced today that investigators for the Company’s Phase ... read more
Monday, January 7, 2013
- Advanced Cell Technology to Present at Biotech Showcase™ 2013Advanced Cell Technology, Inc. (“ACT”) (OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that chairman and CEO Gary Rabin will present ... read more
Thursday, December 20, 2012
- New Scientist Magazine Selects ACT’s Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program As One of ‘10 Ideas That Will Shape The Year’Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the field of regenerative medicine, today announced that its iPS cell-derived human platelet program has ... read more
Wednesday, December 19, 2012
- Advanced Cell Technology Elects Not to Complete Reverse SplitAdvanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the field of regenerative medicine, announced today that it will allow the shareholder approval it ... read more
Monday, December 17, 2012
- ACT Announces Completion of Higher-Dosage Cohort in European Clinical Trial for Stargardt’s Macular DystrophyAdvanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the field of regenerative medicine, today announced treatment of the fifth and sixth patients in ... read more